Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3ETJD | ISIN: US2312693094 | Ticker-Symbol: CUS0
Tradegate
06.06.25 | 08:03
2,120 Euro
+3,92 % +0,080
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CURIS INC Chart 1 Jahr
5-Tage-Chart
CURIS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,9802,30015:43
2,0602,22015:43

Aktuelle News zur CURIS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
26.05.Research and Markets: VISTA Inhibitor Clinical Trials Market Insights and Drug Development Opportunities Report 2025-2028 Featuring Aurigene, Curis, Hummingbird Bioscience, Kineta, PharmAbcine, Sensei Biotherapeutics - ResearchAndMarkets.com293The "VISTA Inhibitor Clinical Trials, Drug Development Opportunities Patent Insight 2025" report has been added to ResearchAndMarkets.com's offering. The landscape of cancer immunotherapy has witnessed...
► Artikel lesen
22.05.CURIS INC - 8-K, Current Report3
19.05.H.C. Wainwright sets $17 target for Curis stock with Buy rating11
07.05.Curis, Inc.: Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)112LEXINGTON, Mass., May 6, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally...
► Artikel lesen
06.05.Curis highlights progress in lymphoma and AML trials with expanded patient enrollment3
06.05.Curis Inc Q1 Loss Decreases, Beats Estimates210WASHINGTON (dpa-AFX) - Curis Inc (CRIS) announced Loss for first quarter that decreased from the same period last year and beat the Street estimates.The company's earnings came in at -$10.62...
► Artikel lesen
06.05.Curis GAAP EPS of -$1.25 misses by $0.06, revenue of $2.38M misses by $0.22M2
CURIS Aktie jetzt für 0€ handeln
06.05.CURIS INC - 10-Q, Quarterly Report5
06.05.CURIS INC - 8-K, Current Report2
06.05.Curis, Inc.: Curis Provides First Quarter 2025 Business Update90Curis strengthens executive team with the appointment of industry veteran Dr. Ahmed Hamdy as Chief Medical Officer Management to host conference call today at 8:30...
► Artikel lesen
05.05.Earnings Outlook For Curis2
05.05.Curis Q1 2025 Earnings Preview3
01.04.Curis stock price target cut to $16 by H.C. Wainwright11
31.03.Curis targets accelerated approval for emavusertib in PCNSL with 12-18 month enrollment timeline4
31.03.Curis Inc Q4 Loss Narrows310WASHINGTON (dpa-AFX) - Curis Inc (CRIS) announced Loss for fourth quarter of -$9.618 millionThe company's earnings totaled -$9.618 million, or -$1.25 per share. This compares with -$11.712 million...
► Artikel lesen
31.03.Curis strebt beschleunigte Zulassung für Krebsmedikament Emavusertib an15
31.03.Curis GAAP EPS of -$1.25, revenue of $3.35M4
31.03.Curis, Inc.: Curis Provides Fourth Quarter 2024 Business Update132FDA and EMA discussions completed to support a potential accelerated approval path in both US and EU Orphan Drug Designation for PCNSL granted in both US and EU Management...
► Artikel lesen
28.03.CURIS INC - 8-K, Current Report3
10.12.24Curis reports promising AML study results12
Weiter >>
26 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1